Final adult height in Korean children with idiopathic growth hormone deficiency after growth hormone treatment

Read full text Summarise with VIRAT
Authors: Min Hyung Cho, Se Jin An, Young Suk Shim, Jin Soon Hwang, Hae Sang Lee
Cited by: 0
References: 29

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study evaluated final adult height (FAH) outcomes and associated predictive factors in patients with idiopathic growth hormone deficiency (IGHD) treated with recombinant human growth hormone (GH). We retrospectively analyzed medical records of prepubertal patients who initiated GH treatment from August 2003. As of July 2024, FAH data were available for 60 patients (40 males, 20 females). The patients started GH therapy at a mean age of 8.5 years and were treated for an average of 6.5 years. Mean height improved from − 2.6 to − 1.1 standard deviation score (SDS) following treatment. GH treatment was initiated at a significantly younger age in females. Mean FAH was 168.5 ± 4.4 cm (− 1.1 ± 0.8 SDS) in males and 156.0 ± 3.3 cm (− 1.1 ± 0.7 SDS) in females. FAH SDS was comparable to target height SDS. Multiple regression analysis showed that FAH SDS was positively associated with initial height SDS (B = 0.72, 95% CI 0.270–1.182) and negatively associated with baseline insulin-like growth factor-1 (IGF-1) SDS (B = − 0.347, 95% CI − 0.501 to − 0.192) (Adjusted R 2 = 0.295, p < 0.001). In conclusion, GH therapy significantly improved final height in patients with IGHD. A greater treatment benefit was observed in those with taller initial height and lower IGF-1 levels prior to treatment initiation.

Fields of Study & Subjects

Growth Hormone and Insulin-like Growth Factors Pituitary Gland Disorders and Treatments Hypothalamic control of reproductive hormones

Publication details

Journal / source
Scientific Reports
Volume
16
Issue
1
Publication date
25 March 2026
Language
EN